Interneuron Pharmaceuticals has completed the acquisition of Cardiovascular Pharmacology and Engineering Consultants, and in so doing has gained rights to develop bucindolol, a beta antagonist in advanced clinical testing for the therapy of heart failure.
The National Institutes of Health and Veterans Administration have already committed multi-million dollar funding for the Phase III Beta Blocker Evaluation of Survival Trial (BEST) with the drug, which is scheduled to begin in 1995 and is expected to include approximately 3,000 patients at several centers across the USA. Interneuron itself has also committed $2 million to the trial.
Bucindolol was selected for inclusion in the BEST studies "because of its unique action on the heart muscle, which differentiates it from other marketed or investigational beta blockers," according to Interneuron chief executive Glenn Cooper. To manage development of bucindolol, Interneuron formed a wholly-owned subsidiary, Intercardia, in June.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze